Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Legha

Showing results (91-100 of 179) with videos related to

Pageof 18
Sort By:
Oncology Reports|July 30, 1999
Phase II trial of doxil for patients with metastatic melanoma refractory to frontline therapyJ A Ellerhorst, A Bedikian, S Ring, et al.
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|January 1, 1980
m-AMSA: a new anticancer agentM Rozencweig, D D Von Hoff, S S Legha, et al.
Cancer|May 1, 1984
Combination chemotherapy of metastatic breast carcinoma with cyclophosphamide, adriamycin, and peptichemioS S Legha, J A Ajani, G R Blumenschein, et al.
Radiology Case Reports|August 15, 2022
The Post-Operative Mammographic Appearance of Lymphovenous Bypass and Vascularized Lymph Node TransferEmily S Nia, Miral M Patel, Edward I Chang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 1998
Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanomaS S Legha, S Ring, O Eton, et al.
Cancer Treatment Reports|December 1, 1987
Phase I clinical investigation of benzisoquinolinedioneS S Legha, S Ring, M Raber, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 1, 1996
Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alphaS S Legha, S Ring, A Bedikian, et al.
Anti-Cancer Drugs|February 1, 1992
Clinical pharmacokinetics of ifosfamide in combination with N-acetylcysteineJ A Benvenuto, W Ayele, S S Legha, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1993
Phase II study of vindesine and dacarbazine with or without non-specific stimulation of the immune system in patients with metastatic melanomaC F Verschraegen, S S Legha, E M Hersh, et al.
European Journal of Cancer & Clinical Oncology|December 1, 1981
AMSA toxicity in patients with abnormal liver functionP S Mahal, S S Legha, M Valdivieso, et al.
Pageof 18

Showing results (91-100 of 179) with videos related to

Sort By:
Pageof 18
Oncology Reports|July 30, 1999
Phase II trial of doxil for patients with metastatic melanoma refractory to frontline therapyJ A Ellerhorst, A Bedikian, S Ring, et al.
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|January 1, 1980
m-AMSA: a new anticancer agentM Rozencweig, D D Von Hoff, S S Legha, et al.
Cancer|May 1, 1984
Combination chemotherapy of metastatic breast carcinoma with cyclophosphamide, adriamycin, and peptichemioS S Legha, J A Ajani, G R Blumenschein, et al.
Radiology Case Reports|August 15, 2022
The Post-Operative Mammographic Appearance of Lymphovenous Bypass and Vascularized Lymph Node TransferEmily S Nia, Miral M Patel, Edward I Chang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 1998
Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanomaS S Legha, S Ring, O Eton, et al.
Cancer Treatment Reports|December 1, 1987
Phase I clinical investigation of benzisoquinolinedioneS S Legha, S Ring, M Raber, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 1, 1996
Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alphaS S Legha, S Ring, A Bedikian, et al.
Anti-Cancer Drugs|February 1, 1992
Clinical pharmacokinetics of ifosfamide in combination with N-acetylcysteineJ A Benvenuto, W Ayele, S S Legha, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1993
Phase II study of vindesine and dacarbazine with or without non-specific stimulation of the immune system in patients with metastatic melanomaC F Verschraegen, S S Legha, E M Hersh, et al.
European Journal of Cancer & Clinical Oncology|December 1, 1981
AMSA toxicity in patients with abnormal liver functionP S Mahal, S S Legha, M Valdivieso, et al.
Pageof 18